Compare RGLD & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | EXAS |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6B | 19.3B |
| IPO Year | N/A | N/A |
| Metric | RGLD | EXAS |
|---|---|---|
| Price | $277.55 | $102.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $218.43 | $81.27 |
| AVG Volume (30 Days) | 947.7K | ★ 2.3M |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 66.97 | N/A |
| EPS | ★ 7.28 | N/A |
| Revenue | $849,255,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $23.03 | $19.40 |
| Revenue Next Year | $71.74 | $13.51 |
| P/E Ratio | $36.42 | ★ N/A |
| Revenue Growth | ★ 28.17 | 14.47 |
| 52 Week Low | $135.68 | $38.81 |
| 52 Week High | $265.48 | $102.66 |
| Indicator | RGLD | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 84.79 | 79.87 |
| Support Level | $216.53 | $101.51 |
| Resistance Level | $244.86 | $102.56 |
| Average True Range (ATR) | 8.07 | 0.33 |
| MACD | 2.62 | -0.62 |
| Stochastic Oscillator | 98.70 | 66.19 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.